Q2 2024 Curis Inc Earnings Call Transcript
Key Points
- Curis Inc (CRIS) reported an objective response rate over 50% in their TakeAim Lymphoma study, indicating promising results for emavusertib in combination with ibrutinib.
- Emavusertib has been granted orphan drug designation for primary CNS lymphoma by the European Commission, providing benefits such as 10 years of market exclusivity.
- The company is making progress in expanding clinical sites, aiming for 30 sites in the US and Europe by year-end.
- Curis Inc (CRIS) is exploring a novel mechanism for emavusertib in treating relapsed/refractory AML, with positive responses in patients with splicing factor and FLT3 mutations.
- The company has initiated a study of emavusertib in combination with azacitidine and venetoclax in frontline AML, with initial safety data expected later this year.
- Curis Inc (CRIS) reported a net loss of $11.8 million for the second quarter of 2024, slightly less than the $12 million loss in the same period in 2023.
- Research and development expenses increased to $10.3 million in Q2 2024 from $10 million in Q2 2023, indicating rising costs.
- General and administrative expenses rose to $4.8 million in Q2 2024 from $4.2 million in Q2 2023, primarily due to higher employee-related costs.
- The company's cash, cash equivalents, and investments totaled $28.4 million, which is expected to sustain operations only into the first quarter of 2025.
- The competitive landscape in AML is crowded, posing challenges for Curis Inc (CRIS) in differentiating its offerings.
Good morning, ladies and gentlemen. And welcome to the Curis provide second-quarter 2024 Business Update Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. (Operator Instructions)
This call is being recorded on Thursday, August 1, 2024. I would now like to turn the conference over to Diantha Duvall. Please go ahead.
Thank you and welcome to Curis second quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the Investor section of our website at www.curis.com to find our second quarter 2024 business update press release and related financial tables.
I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
